Compelling New Cancer Technology: CEO Leslie Chong Introduces OV CF33


Imugene’s CEO & Managing Director Leslie Chong introduces Professor Fong at the CF33 launch at Rockpool, Sydney on July 17th. Leslie details the exciting prospect this oncolytic virus represents to Imugene.

CF33 is a chimeric vaccinia poxvirus from the lab of Professor Yuman Fong, Chair of Surgery at City of Hope, and a noted expert in the oncolytic virus field.

Oncolytic viruses (OVs) are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

OVs have the potential to transform oncology by directly causing tumour cell death, and also by delivering a potent payload in a targeted fashion that activates the immune system.